Cabergoline is a dopaminergic agonist relatively specific for the D2 receptor and much longer-acting than other dopamine agonists. We conducted a randomized, placebo-controlled, double-blind study of cabergoline in 188 levodopa/carbidopa-treated patients with suboptimally controlled Parkinson's disease (PD). The cabergoline patients had significantly better Activities of Daily Living (p = 0.032) and Motor Examination (p = 0.031) scores at the conclusion of the trial compared with the placebo group. The daily levodopa dose for the cabergoline patients decreased 18% compared with a 3% reduction for the placebo group (p < 0.001). The amount of time in the "on" state increased more in the cabergoline group (p = 0.022). The side-effect was similar to that seen with other dopamine agonists, and cabergoline was generally well tolerated. We conclude that cabergoline is an effective adjunct to levodopa for the treatment of PD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/wnl.46.4.1062 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drugs associated with tachyphylaxis: results from a retrospective pharmacovigilance study using disproportionality analysis.
Eur J Hosp Pharm
January 2025
Pharmacology & Therapeutics, College of Medicine and Health Sciences, Arabian Gulf University, Manama, Bahrain
Background: Tachyphylaxis is the rapid development of drug tolerance following repeated administration.
Objectives: To evaluate the United States Food and Drug Administration Adverse Event Reporting System (USFDA AERS) data for drugs significantly associated with tachyphylaxis using disproportionality analysis.
Methods: Disproportionality analysis was used for detecting safety signals for identifying drugs associated with tachyphylaxis.
Advances in pharmacological treatment of Cushings disease.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
July 2024
Department of Endocrinology ＆Metabolism, West China Hospital, Sichuan University, Chengdu 610041.
Cushing's disease is a rare endocrine disorder characterized by hypercortisolism. Chronic elevated cortisol levels can lead to dysfunction or complications in multiple organs of systems, including cardiovascular, glucose, and bone metabolism, severely impacting patients' quality of life and posing life-threatening risks. Surgery is the first-line treatment for Cushing's disease.
View Article and Find Full Text PDFAcromegaly: diagnostic challenges and individualized treatment.
Expert Rev Endocrinol Metab
January 2025
Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.
Introduction: Acromegaly is due in almost all cases to a GH-secreting pituitary tumor. GH and IGF-1 excesses lead to its multi-system clinical manifestations and comorbidities. Acromegaly is under-diagnosed and typically presents with advanced disease.
View Article and Find Full Text PDFA retrospective observational clinical study of triple negative breast cancer cases treated with Di Bella Method: A preliminary data.
Neuro Endocrinol Lett
December 2024
Di Bella Foundation, Via Guglielmo Marconi 51 Bologna, 40122 Italy.
Objectives: Triple negative breast cancer (TNBC) is a distinct subtype of breast cancer that has a poor prognosis due to the lack of effective therapeutic agents. Since a significant proportion of human surgical samples of TNBC expressed mRNA for the growth hormone (GH), growth hormone-releasing hormone (GHRH), and gonadotropin-releasing hormone (GnRH) receptors, and the mitogenic proliferative activity of GH, GHRH, and GnRH, have been identified as effective therapeutic targets for somatostatin and its analogs and GnRH analogs, Di Bella Method (DBM), a combination of hormonal analogs and vitamins, was introduced to target and inhibit solid tumors. The present study aimed to improve the prognosis of TNBC using DBM in women with TNBC.
View Article and Find Full Text PDFGenotype-negative multiple endocrine neoplasia type 1 with prolactinoma, hyperparathyroidism, and subclinical Cushing's syndrome accompanied by hyperglycemia: a case report.
Front Endocrinol (Lausanne)
December 2024
Diabetes Center, Ohta Nishinouchi Hospital, Koriyama, Fukushima, Japan.
Article Synopsis
- Multiple endocrine neoplasia type 1 (MEN1) is a rare genetic disorder characterized by tumors in multiple endocrine glands, but some patients may lack the genetic markers typically associated with the condition.
- A 56-year-old woman with a history of a macroprolactinoma, primary hyperparathyroidism, and a cortisol-producing adrenal adenoma was diagnosed with MEN1 despite being genotype-negative, raising concerns about the reliability of genetic testing.
- The case highlights that genotype-negative MEN1 can involve serious complications and emphasizes the importance of recognizing clinical symptoms like glucose intolerance and tumor manifestations to avoid delayed diagnoses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!